Hospital Acquired Disease Testing Market Size To Hit US$ 27.7 Billion By 2028 | CAGR 17.57%

PRESS RELEASE
Published April 6, 2023

IMARC Group has recently released a new research study titled "Hospital Acquired Disease Testing Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2023-2028", The global hospital acquired disease testing market size reached US$ 10.3 Billion in 2022. Looking forward, IMARC Group expects the market to reach US$ 27.7 Billion by 2028, exhibiting a growth rate (CAGR) of 17.57% during 2023-2028. This report can serve as an excellent guide for investors, researchers, consultants, marketing strategists and all those who are planning to foray into the market in any form.

Hospital acquired disease, or nosocomial infection, is a name given to ailments that are caused by infectious toxin agents in hospitals and medical clinics. They can be categorized into urinary tract infection (UTI), bloodstream infections, surgical site infection (SSI), pneumonia, methicillin-resistant staphylococcus aureus (MRSA), etc. Some of the common reasons behind these types of hospital acquired diseases include lack of proper hygiene in the hospital setting, below-par maintenance, a rise in the prevalence of multi-drug resistant organisms (MDROs), etc. In several cases, they have also been traced to the own microbiome of the patient and prove extremely harmful to their health.

Request to Get the Sample Report: https://www.imarcgroup.com/hospital-acquired-disease-testing-market/requestsample

Market Trends:

The rising incidences of nosocomial infections, such as catheter-related bloodstream infection (CRBSI) and central line-associated bloodstream infection (CLABSI) are primarily driving the hospital acquired disease testing market. Furthermore, the elevating focus among the leading manufacturers towards developing technologically advanced and efficient testing tools is also positively influencing the market growth. In line with this, the escalating adoption of innovative diagnostic techniques, including microarrays, real-time location systems (RTLSs), polymerase chain reaction (PCR), and solid phase hybridization, is acting as another significant growth-inducing factor. Additionally, the expanding medical tourism industry and the increasing prevalence of modernized healthcare infrastructures are expected to propel the hospital acquired disease testing market over the forecasted period.

Hospital Acquired Disease Testing Market Report


Competitive Landscape With Key Players:

The competitive landscape of the hospital acquired disease testing market has been studied in the report with the detailed profiles of the key players operating in the market.

Global Hospital Acquired Disease Testing Market Key Companies: 

• Abbott Laboratories
• Alere, Inc.
• Becton, Dickinson and Company
• bioMérieux SA
• Hoffmann-La Roche Ltd.
• Hologic, Inc.
• QIAGEN
• Siemens Healthcare
• Diatherix Laboratories, Inc.
• Meridian Bioscience, Inc.
• Thermo Fisher Scientific, Inc. (Life Technologies Corporation)
• Cepheid, Inc.

Market Segmentation:

The report has segmented the hospital acquired disease testing market on the basis of indication and region.

Breakup by Indication:

• UTI (Urinary Tract Infection)
• SSI (Surgical Site Infection)
• Pneumonia
• Bloodstream Infections
• MRSA (Methicillin-Resistant Staphylococcus Aureus)
• Others

Breakup by Region:

• North America: (United States, Canada)
• Asia Pacific: (China, Japan, India, South Korea, Australia, Indonesia, Others)
• Europe: (Germany, France, United Kingdom, Italy, Spain, Russia, Others)
• Latin America: (Brazil, Mexico, Others)
• Middle East and Africa

Speak to Analyst: https://www.imarcgroup.com/request?type=report&id=1128&flag=C

Key Highlights of the Report:               

• Market Performance (2017-2022)
• Market Outlook (2023-2028)
• Industry Trends
• Market Drivers and Success Factors
• The Impact of COVID-19 on the Global Market
• Value Chain Analysis
• Structure of the Global Market
• Comprehensive mapping of the competitive landscape

Note: This report can serve as an excellent guide for investors, researchers, consultants, marketing strategists and all those who are planning to foray into the market in any form.

List of Tables

Table 1: Global: Hospital Acquired Disease Testing Market: Key Industry Highlights, 2022 and 2028
Table 2: Global: Hospital Acquired Disease Testing Market Forecast: Breakup by Indication (in Million US$), 2023-2028
Table 3: Global: Hospital Acquired Disease Testing Market Forecast: Breakup by Region (in Million US$), 2023-2028
Table 4: Global: Hospital Acquired Disease Testing Market: Competitive Structure
Table 5: Global: Hospital Acquired Disease Testing Market: Key Players

If you need specific information that is not currently within the scope of the report, we will provide it to you as a part of the customization.

Browse More Hospital Acquired Disease Testing Market Reports by Region:

Note: We are in the process of updating our reports. If you want to receive the latest research data covering the time period from 2023 to 2028, along with industry trends, market size, and competitive analysis, click on the request sample report. The team would be able to deliver the latest version of the report in a quick turnaround time.

United States Hospital Acquired Disease Testing Market Report

Asia Pacific Hospital Acquired Disease Testing Market

Europe Hospital Acquired Disease Testing Market

About Us:

IMARC Group is a leading market research company that offers management strategy and market research worldwide. We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses.

Our offerings include comprehensive market intelligence in the form of research reports, production cost reports, feasibility studies, and consulting services. Our team, which includes experienced researchers and analysts from various industries, is dedicated to providing high-quality data and insights to our clientele, ranging from small and medium businesses to Fortune 1000 corporations.

IMARC’s information products include major market, scientific, economic and technological developments for business leaders in pharmaceutical, industrial, and high technology organizations. Market forecasts and industry analysis for biotechnology, advanced materials, pharmaceuticals, food and beverage, travel and tourism, nanotechnology and novel processing methods are at the top of the company’s expertise.

Media Contact:
Company Name: IMARC Group
Contact Person: Elena Anderson
Email: sales@imarcgroup.com
Phone: +1-631-791-1145
Address: 134 N 4th St
City: Brooklyn
State: NY
Country: United States
Read Newsletter: https://www.linkedin.com/newsletters/industry-news-about-6929400456628637696

 

IMARC